



ASX Announcement

July 28, 2021

CHIMERIC LICENSES NOVEL SOLID TUMOR CAR T THERAPY FROM WORLD-RENOWNED CELL THERAPY CENTRE UNIVERSITY OF PENNSYLVANIA

- Chimeric has obtained the exclusive license to a novel CAR T for solid tumors from the University of Pennsylvania (Penn)
- The CDH17 CAR T has demonstrated the complete eradication of tumor cells with no evidence of toxicity in preclinical studies
- A phase 1 clinical trial is planned for 2022
- The novel CAR T targets CDH17, giving it broad applicability in neuroendocrine tumors and the most common gastrointestinal tumors
- Attractive licensing fees funded through existing cash reserves with industry standard commercial royalties
- The University of Pennsylvania is a globally recognized leader in cellular immunotherapy and widely known for being home to the 1st FDA approved CAR T therapy.

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), a clinical-stage cell therapy company committed to bringing the promise of cell therapy to life for more patients, has entered into an exclusive licensing agreement with world renowned cell therapy centre, the University of Pennsylvania (Penn), for the first CDH17 CAR (chimeric antigen receptor) T cell therapy.

The novel CDH17 CAR T cell therapy targets CDH17, an oncogenic factor associated with poor prognosis and metastasis in neuroendocrine tumors as well as the most common gastrointestinal tumors including colorectal cancer, pancreatic cancer and gastric cancer.

More than a decade of research and optimization has gone into development of the novel CDH17 CAR T cell therapy, developed by leading cellular immunotherapy scientist Xianxin Hua, MD, PhD, and his team. Dr Hua is a professor of Cancer Biology in Penn’s Perelman School of Medicine, an investigator at the Abramson Family Cancer Research Institute and a Harrington Scholar Innovator.

“Chimeric is incredibly excited to bring the CDH17 CAR T cell therapy into our pipeline. Our focus is on developing cell therapies that have the potential to be curative for patients and we believe that this CDH17 CAR T cell therapy has that transformative potential. We are very much looking forward to working with Dr Hua and his team to bring this CAR T to the clinic as soon as possible,” said Jennifer Chow, Chimeric COO.

The CDH17 CAR T cell therapy is a next or 3rd generation CAR T cell therapy that utilizes novel technology to specifically address the challenges of solid tumors. Preclinical studies of the



CDH17 CAR T have demonstrated safety, with no toxicity to normal tissues, and promising efficacy with complete eradication of tumor cells and no relapse of the tumor.

“The preclinical studies indicate that our CDH17 CAR T marks the recognition of an entirely new class of solid tumor antigen targets, that are highly susceptible to CAR T attack on tumor cells yet masked from attack by the CAR T in normal tissues,” said Dr Hua.

Development is currently underway for a phase 1 clinical trial that is planned to begin in 2022 at the University of Pennsylvania.

A three-year commitment for further research and development has been made to Dr Hua and Penn.

Under the terms of the license agreement, Chimeric Therapeutics acquires the exclusive rights to develop and commercialize the CDH17 CAR T cell therapy for which it has agreed to pay Penn license fees, development milestones and royalty payments based on commercial net sales. Upfront fees associated with the license agreement will be funded entirely from existing cash reserves.

The University of Pennsylvania is a globally recognized leader in cellular immunotherapy and widely known for being home to the 1st FDA approved CAR T therapy.

The Chimeric team will be leveraging its unique cell therapy expertise to ensure the timely development and commercialization of the novel CDH17 CAR T cell therapy, bringing the promise of cell therapy and curative potential to more patients with cancer.

Chimeric’s Executive Chairman Paul Hopper said “We are delighted to have secured the exclusive rights to this promising asset from one of the world’s pre-eminent cell therapy centres which has been a powerhouse in CAR T innovation for many years. We look forward to utilizing the deep cell therapy expertise of our team to develop and commercialize this CAR T.”

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.



Chimeric Therapeutics is currently in a phase 1 clinical trial for our lead asset, CLTX CAR T. CLTX CAR T is a novel and promising CAR T therapy for the treatment of patients with Glioblastoma (GBM) developed by scientists at the City of Hope Medical Centre in California.

Chimeric Therapeutics is now actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Operating Officer
Chimeric Therapeutics
P: +9087238387
W: www.chimerictherapeutics.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au